Voloridge Investment Management LLC Decreases Position in Ascendis Pharma A/S (NASDAQ:ASND)

Voloridge Investment Management LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 298,996 shares of the biotechnology company's stock after selling 98,017 shares during the period. Voloridge Investment Management LLC owned approximately 0.49% of Ascendis Pharma A/S worth $41,163,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S in the fourth quarter worth $28,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the period. Blue Trust Inc. lifted its stake in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. Quarry LP purchased a new stake in Ascendis Pharma A/S during the 4th quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC grew its position in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have weighed in on ASND shares. Evercore ISI boosted their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $180.00 to $250.00 in a research note on Monday, May 5th. Wedbush increased their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Finally, Royal Bank of Canada raised their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Price Performance

ASND traded up $1.95 on Monday, hitting $162.00. The company had a trading volume of 212,034 shares, compared to its average volume of 487,685. The stock has a fifty day simple moving average of $157.41 and a 200-day simple moving average of $143.80. The firm has a market capitalization of $9.88 billion, a P/E ratio of -22.82 and a beta of 0.41. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. Equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.